Drugmakers shaped policy amid the drug crisis

News

Drugmakers shaped policy amid the drug crisis

Purdue Pharma agreed to pay more than $600 million in fines in 2007 for misleading the public about the risks of OxyContin.
Brands and dosages of fentanyl, a narcotic that is typically administered to people with chronic pain, including end-stage cancer patients.
Purdue Pharma offices in Stamford, Conn. In 2007, the company pleaded agreed to pay more than $600 million in fines for misleading the public about the risks of OxyContin.
Keith Humphreys, a professor of psychiatry and behavioral sciences at Stanford University on Aug. 29, 2016. “You can go a long, long way in getting what you want when you have a lot of money,” he says.
Food and Drug Administration Commissioner Dr. Margaret Hamburg speaks during an event in the East Room of the White House in Washington in 2014 argued that the number of Americans living in pain justified keeping painkillers accessible.
Keith Humphreys, a professor of psychiatry and behavioral sciences at Stanford University on Aug. 29, 2016. “You can go a long, long way in getting what you want when you have a lot of money,” he says.
Dr. Nathaniel Katz, a former adviser to the Food and Drug Administration, and currently CEO of Analgesic Solutions, implored an FDA panel to support tougher requirements to manage opioid risks in 2010.

Drugmakers shaped policy amid the drug crisis

Purdue Pharma agreed to pay more than $600 million in fines in 2007 for misleading the public about the risks of OxyContin.
Brands and dosages of fentanyl, a narcotic that is typically administered to people with chronic pain, including end-stage cancer patients.
Purdue Pharma offices in Stamford, Conn. In 2007, the company pleaded agreed to pay more than $600 million in fines for misleading the public about the risks of OxyContin.
Keith Humphreys, a professor of psychiatry and behavioral sciences at Stanford University on Aug. 29, 2016. “You can go a long, long way in getting what you want when you have a lot of money,” he says.
Food and Drug Administration Commissioner Dr. Margaret Hamburg speaks during an event in the East Room of the White House in Washington in 2014 argued that the number of Americans living in pain justified keeping painkillers accessible.
Keith Humphreys, a professor of psychiatry and behavioral sciences at Stanford University on Aug. 29, 2016. “You can go a long, long way in getting what you want when you have a lot of money,” he says.
Dr. Nathaniel Katz, a former adviser to the Food and Drug Administration, and currently CEO of Analgesic Solutions, implored an FDA panel to support tougher requirements to manage opioid risks in 2010.
click here to add your event
Area Events
click here to add your event
Area Events